Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Daré Bioscience ( (DARE) ) just unveiled an update.
On July 14, 2025, Daré Bioscience announced positive interim results from its Phase 3 clinical trial of Ovaprene®, a hormone-free monthly intravaginal contraceptive. The trial’s data safety monitoring board recommended continuing the study without modification, as no new safety concerns were identified. Approximately 9% of participants experienced pregnancy, aligning with expectations, while 17% discontinued due to vaginal odor. Participants expressed a high likelihood of using Ovaprene if available, highlighting its potential to meet the demand for hormone-free contraceptive options. Bayer has the option to commercialize Ovaprene in the U.S., potentially providing significant financial benefits to Daré.
The most recent analyst rating on (DARE) stock is a Buy with a $12.00 price target. To see the full list of analyst forecasts on Daré Bioscience stock, see the DARE Stock Forecast page.
Spark’s Take on DARE Stock
According to Spark, TipRanks’ AI Analyst, DARE is a Underperform.
Daré Bioscience’s overall stock score is predominantly influenced by its financial instability, as reflected in the financial performance score. The company faces serious financial distress with negative equity and high liabilities. While there is potential upside from strategic initiatives and possible technical rebounds due to oversold conditions, these are overshadowed by financial and regulatory challenges.
To see Spark’s full report on DARE stock, click here.
More about Daré Bioscience
Daré Bioscience is a biopharmaceutical company focused on women’s health, aiming to address unmet needs in areas such as contraception, sexual health, pelvic pain, fertility, infectious disease, vaginal health, and menopause. The company leverages existing clinical proof of concept or safety data to bring innovative solutions to market efficiently. Daré’s portfolio includes products like XACIATO™ for bacterial vaginosis and potential first-in-category candidates such as Ovaprene®, a hormone-free monthly intravaginal contraceptive, and other women’s health therapies.
Average Trading Volume: 163,225
Technical Sentiment Signal: Sell
Current Market Cap: $22.26M
See more data about DARE stock on TipRanks’ Stock Analysis page.